Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Официальное название

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Adaptive Radiotherapy: a Phase II Study (HELP Trial)

Обзор

This is a proof-of-concept phase II trial to assess the safety (as primary endpoint) and clinical efficacy of neoadjuvant therapy with Elacestrant and PULSAR. The study will enroll 21 postmenopausal patients with early HR+ HER2- node positive BC, clinically staged II-III. Patients will receive Elacestrant 345 mg orally once daily for 24 weeks and PULSAR on the MRI-based breast gross tumor volume (GTVt), consisting of 10 Gy "pulse" every 4 weeks for a maximum of 5 or less in case of radiologic complete response. Surgery will be planned 24 weeks after Elacestrant initiation and at least 2 weeks from the last pulse and will be performed as per recommended clinical practice. Patients will then receive adjuvant systemic therapy as per standard of care and postoperative RT to the locoregional lymph nodes in case of nodal residual disease, if indicated.

Вмешательства

• Препарат Elacestrant
  Preoperative treatment
• Лучевая терапия PULSAR
  Preoperative treatment

Первичные конечные точки

• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks in the pre-operative period, 30 days and 3 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks unitl week 4, then every 4 weeks in the pre-operative period, 30 days and 3 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks in the pre-operative period, 30 days, 3 months, 6 months and 12 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks until week 4 and then every 4 weeks in the pre-operative period, 30 days, 3 months, 6 months and 12 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, at the beginning (week 0) and at the end (week 20) of pre-operative treatment.]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks until week 4 and then every 4 weeks in the pre-operative period, 30 days, 3 months, 6 months and 12 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks until week 4 and then every 4 weeks in the pre-operative period, 30 days, 3 months, 6 months and 12 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks until week 4 and then every 4 weeks in the pre-operative period, 30 days, 3 months, 6 months and 12 months after surgery]
• Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting [Срок оценки: Baseline, every two weeks until week 4 and then every 4 weeks in the pre-operative period, 30 days, 3 months, 6 months and 12 months after surgery]

Критерии участия

Критерии включения

• Histologically proven HR-positive, HER2-negative BC
• Clinical disease stage II-III
• Post-menopausal female patients or male patients
• Eligible for neoadjuvant treatment and subsequent surgery
• No contraindication to MRI
• Patient able to understand and follow instructions during the trial
• Patient able and willing to give written informed consent, signed and dated
• Patient aged at least 50 years old
• Patient with tumor accessible for biopsy and surgery
• Patient with adequate bone marrow function at Screening, confirmed at Baseline, including:

• ANC ≥ 1.5 × 109/L; patients with documented benign cyclical neutropenia are eligible if white blood cell count is ≥ 1.5 × 109/L, with ANC ≥ 1.0 × 109/L, leukocytes ≥ 4.0 × 109/L, and lymphocytes ≥ 0.6 × 109/L;
• platelets ≥ 100 × 109/L;
• hemoglobin ≥ 9 g/dL (may have been transfused);
• International Normalized Ratio (INR) < 1.5×Upper Limit of Normal (ULN); patients treated with vitamin K antagonist are eligible if INR < 3
• Patient with adequate hepatic function at Screening, confirmed at Baseline, defined by:

a. total bilirubin level ≤1.5×ULN; patients with documented Gilbert disease are allowed if total bilirubin ≤3×ULN; aspartate aminotransferase (AST) level ≤2.5×ULN, and alanine aminotransferase (ALT) level ≤2.5×ULN,

• Patient with adequate renal function at Screening, confirmed at Baseline, defined by eGFR ≥ 30 mL/min using 2021 CKD-EPI creatinine equation
• Patient with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Life expectancy of at least 12 months according to the Investigator's judgement

Критерии исключения

• 1\. Patients with stage IV disease 2. Patients with a history of any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, based on the Investigator's judgement, provides a reasonable suspicion of a disease or condition that contraindicates the use of RT and/or Elacestrant or that might affect the interpretation of the trial results or render the patient at high risk for treatment complications.

3\. Patients with any significant co-morbidity which, according to the Investigator's judgement, makes patient compliance to trial conditions unlikely.

4\. Patients with previous malignant disease (other than the tumor disease for this trial) within the last five (5) years (except adequately treated non-melanoma skin cancers and carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least two (2) years prior to Screening, and the patient is deemed to have been cured with no additional therapy required or anticipated to be required.

5\. Patients with a history of uncontrolled intercurrent illness. 6. Patients with a known prior hypersensitivity or contraindications to Elacestrant or any component in its formulations.

7\. Patients with severe acute or chronic medical conditions, including:

• Immune colitis
• Inflammatory bowel disease
• History of severe vomiting or diarrhea not having resolved to Grade 1 at Baseline
• Immune pneumonitis
• Pulmonary fibrosis
• Psychiatric conditions including recent (within the last year) or active suicidal ideation or behavior
• Laboratory abnormalities that may increase the risk associated with trial participation or trial treatment administration or may interfere with the interpretation of trial results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this trial.

8\. Patients with a history of small intestine resection surgery or other major gastrointestinal surgery.

9\. Patients with an active infection requiring systemic therapy with antibiotics (at both Screening and Baseline).

10\. Patients with a known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome or multi-drug-resistant gram-negative bacteria.

11\. Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at Screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody Screening test positive).

12\. Patients with increased anesthesiological risk (e.g. known or predicted difficult airway) if general anesthetic is required.

13\. Premenopausal patients (defined as any woman who is not surgically sterile with a hysterectomy and/or bilateral oophorectomy or >12 months of amenorrhea and at least 50 years of age) 14. Patients aged less than 50 years old. 15. Patients with a known history of drug/substance abuse. 16. Patients participating in any other clinical trial within 30 days before Screening.

17\. Patients receiving any other treatment that, in the opinion of the Investigator, might interfere with the trial.

18\. Concomitant use of strong or moderate CYP3A4 inhibitors should be avoided and an alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered.

19\. Concomitant use of strong or moderate CYP3A4 inducers should be avoided and an alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered.

20\. Patients with a current drug or substance abuse. 21. Patients receiving chronic concurrent therapy within two (2) weeks before the trial treatment or expected therapy during the trial treatment period with:

<!-- -->

• Corticosteroids (except systemic corticosteroids up to 10 mg prednisolone or equivalent daily dose).
• Immunosuppressive agents.
• Antibiotics.
• Any other anticancer therapy or concurrent anticancer treatment. 22. Patients who are unable to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial.

23\. Patients who are unlikely to comply with the Protocol requirements, instructions and trial-related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial.

24\. Patients with legal incapacity or limited legal capacity. 25. Patients with any condition which results in an undue risk for the patient during the trial participation according to the Investigator.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Италия · 1 центр

• AOU Careggi Radiation Oncology Unit — Florence

Идентификаторы

NCT: NCT07005882 · HELP Trial · 2025-520762-22-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗